173 related articles for article (PubMed ID: 23448822)
41. The Food and Drug Administration risk evaluation and mitigation strategy.
Craig DS
J Pain Palliat Care Pharmacother; 2010 Jun; 24(2):145-8. PubMed ID: 20504137
[TBL] [Abstract][Full Text] [Related]
42. Turalio risk evaluation and mitigation strategy for treatment of tenosynovial giant cell tumor: framework and experience.
Dharmani C; Wang E; Salas M; McCabe C; Diggs A; Choi Y; Jiang J; Keedy VL
Future Oncol; 2022 Apr; 18(13):1595-1607. PubMed ID: 35105158
[TBL] [Abstract][Full Text] [Related]
43. Symptom experience after solid organ transplantation.
Kugler C; Geyer S; Gottlieb J; Simon A; Haverich A; Dracup K
J Psychosom Res; 2009 Feb; 66(2):101-10. PubMed ID: 19154852
[TBL] [Abstract][Full Text] [Related]
44. A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder.
Foy JM; Earls MF
Pediatrics; 2005 Jan; 115(1):e97-104. PubMed ID: 15629972
[TBL] [Abstract][Full Text] [Related]
45. NCCN Oncology Risk Evaluation and Mitigation Strategies White Paper: Recommendations for Stakeholders.
Johnson PE; Dahlman G; Eng K; Garg R; Gottlieb S; Hoffman JM; Howell P; Jahanzeb M; Johnson S; Mackler E; Rubino M; Sarokhan B; Marc Stewart F; Tyler T; Vose JM; Weinstein S; Li EC; Demartino J;
J Natl Compr Canc Netw; 2010 Sep; 8 Suppl 7():S7-S27. PubMed ID: 20947724
[TBL] [Abstract][Full Text] [Related]
46. Case histories in pharmaceutical risk management.
McCormick CG; Henningfield JE; Haddox JD; Varughese S; Lindholm A; Rosen S; Wissel J; Waxman D; Carter LP; Seeger V; Johnson RE
Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S42-55. PubMed ID: 19767156
[TBL] [Abstract][Full Text] [Related]
47. Risk management and post-marketing surveillance of CNS drugs.
Henningfield JE; Schuster CR
Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S56-64. PubMed ID: 19767155
[TBL] [Abstract][Full Text] [Related]
48. Risk management of drug products and the U.S. Food and Drug Administration: evolution and context.
Leiderman DB
Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S9-S13. PubMed ID: 19307069
[TBL] [Abstract][Full Text] [Related]
49. Industry Review of Best Practices for Risk Management of Drug-Induced Liver Injury from Development to Real-World Use.
Marquez L; Raheja R; Chan-Liston M; Marcinak J; Estilo A; Pineda Salgado L; Jiang J; Chang C; Beninger P
Drug Saf; 2024 Jan; 47(1):1-22. PubMed ID: 37874451
[TBL] [Abstract][Full Text] [Related]
50. Don't sell out safety: a call to preserve risk evaluation and mitigation strategies to reduce harm to patients and the public in the U.S.
Worthy SL
J Pharm Policy Pract; 2016; 9():2. PubMed ID: 26798484
[TBL] [Abstract][Full Text] [Related]
51. Rurality and other factors associated with adherence to immunosuppressant medications in community-dwelling solid-organ transplant recipients.
Sankaranarayanan J; Collier D; Furasek A; Reardon T; Smith LM; McCartan M; Langnas AN
Res Social Adm Pharm; 2012; 8(3):228-39. PubMed ID: 21856247
[TBL] [Abstract][Full Text] [Related]
52. Rosiglitazone, myocardial ischemic risk, and recent regulatory actions.
Bourg CA; Phillips BB
Ann Pharmacother; 2012 Feb; 46(2):282-9. PubMed ID: 22298606
[TBL] [Abstract][Full Text] [Related]
53. Comparative effectiveness of risk mitigation strategies to prevent fetal exposure to mycophenolate.
Sarayani A; Albogami Y; Elkhider M; Hincapie-Castillo JM; Brumback BA; Winterstein AG
BMJ Qual Saf; 2020 Aug; 29(8):636-644. PubMed ID: 31649165
[TBL] [Abstract][Full Text] [Related]
54. Implementation and Use of Risk Evaluation and Mitigation Strategies Programs in Practice: A Scoping Review of the Literature.
Tajchman S; Lawler B; Spence N; Haque S; Quintana Y; Ateya M
Appl Clin Inform; 2022 Oct; 13(5):1151-1160. PubMed ID: 36482261
[TBL] [Abstract][Full Text] [Related]
55. Long-acting β₂ agonists for asthma: a clinical paradox.
Williams D
Consult Pharm; 2010 Nov; 25(11):756-9. PubMed ID: 21138824
[TBL] [Abstract][Full Text] [Related]
56. Food safety for the solid organ transplant patient: preventing foodborne illness while on chronic immunosuppressive drugs.
Obayashi PA
Nutr Clin Pract; 2012 Dec; 27(6):758-66. PubMed ID: 23100530
[TBL] [Abstract][Full Text] [Related]
57. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
[TBL] [Abstract][Full Text] [Related]
58. The Risk Evaluation and Mitigation Strategy (REMS) Public Dashboard: Improving Transparency of Regulatory Activities.
Toyserkani GA; Lee JH; Zhou EH
Pharmaceut Med; 2023 Sep; 37(5):349-353. PubMed ID: 37421560
[TBL] [Abstract][Full Text] [Related]
59. The formulary process from a risk management perspective.
Raber JH
Pharmacotherapy; 2010 Jun; 30(6 Pt 2):42S-47S. PubMed ID: 20500043
[TBL] [Abstract][Full Text] [Related]
60. Evolving regulatory landscape with erythropoiesis-stimulating agents and impact on managed care.
Fatodu H
Am J Manag Care; 2010 Mar; 16 Suppl Issues():S74-9. PubMed ID: 20297875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
